Clinical Efficacy and Safety of Once-Daily Dosing of a Novel, Prolonged-Release Oral Morphine Tablet Compared With Twice-Daily Dosing of a Standard Controlled-Release Morphine Tablet in Patients With Cancer Pain: A Randomized, Double-Blind, Exploratory Crossover Study

Journal of Pain and Symptom Management

Volumn 39, Issue 4, 2010, Pages 712-720

  Ridgway, Derry ^a   Sopata, Maciej ^b,c   Burneckis, Arvydas ^d   Jespersen, Lillian ^e   Andersen, Christine ^e  

^a SRA International   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Hospice Palium   (Poland)

^d VILNIUS UNIVERSITY   (Lithuania)

^e Egalet a/s ^*  (Denmark)

Author keywords

analgesia; cancer pain management; comparative study; once daily; opioids; Oral morphine sulfate; prolonged release; randomized

Indexed keywords

ACTISKENAN; EGALET; MORPHINE SULFATE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; EVENING DOSAGE; EXPLORATORY RESEARCH; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; MASS SPECTROMETRY; MORNING DOSAGE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROLONGED RELEASE FORMULATION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SOMNOLENCE; STEADY STATE; TREATMENT DURATION; UTERINE CERVIX CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 77951015384     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.08.013     Document Type: Article

References (21)

1. Homesley H.D., Welander C.E., Muss H.B., and Richards F. Dose range study of morphine sulfate controlled-release. Am J Clin Oncol 9 5 (1986) 449-453
2. Khojasteh A., Evans W., Reynolds R.D., Thomas G., and Savarese J.J. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 5 (1987) 956-961
3. Savarese J.J., Thomas G.B., Homesley H., and Hill C.S. Rescue factor: a design for evaluating long-acting analgesics. Clin Pharmacol Ther 43 (1988) 376-380
4. Lapin J., Houde R.W., Kaiko R.F., et al. Cancer pain management with a controlled-release oral morphine preparation. J Pain Symptom Manage 4 (1989) 146-151
5. Kaiko R.F., Grandy R.P., Oshlack B., et al. The United States experience with oral controlled-release morphine (MS Contin tablets). Cancer 63 (1989) 2348-2354
6. Ferrell B., Wisdom C., Wenzl C., and Brown J. Effects of controlled-release morphine on quality of life for cancer pain. Oncol Nurs Forum 16 (1989) 521-526
7. ® and other opioid analgesics in the United States: 2002-2004. J Pain 6 (2005) 662-672. http://paincenter.wustl.edu/c/BasicResearch/documents/CiceroJPain2005.pd f Last accessed February 26, 2010
8. Sellers E.M., Schuller R., Romach M.K., and Horbay G.L.A. Relative abuse potential of opioid formulations in Canada: a structured field study. J Opioid Manag 2 (2006) 219-227
9. ® dosage units. Proceedings of the 34th Annual Meeting and Exposition of the Controlled Release Society, July 7-11, 2007 (2008), Curran Associates, Inc, Long Beach, California, New York Poster no. 680
10. Babul N., Provencher L., Laberge F., Harsanyi Z., and Moulin D. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 38 (1998) 74-81
11. Hagen N.A., and Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79 7 (1997) 1428-1437
12. Bruera E., Fainsinger R., Spachynski K., et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13 (1995) 1520-1527
13. Hays H., Hagen N., Thirlwell M., et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74 (1994) 1808-1816
14. Boureau F., Saudubray F., d'Arnoux C., et al. A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain. J Pain Symptom Manage 7 7 (1992) 393-399
15. Caraceni A., Cherny N., Fainsinger R., et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 23 3 (2002) 239-255
16. Portenoy R.K., Sciberras A., Eliot L., et al. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 23 (2002) 292-300
17. Farrar J.T., Portenoy R.K., Berlin J.A., Kinman J.L., and Strom B.L. Defining the clinically important difference in pain outcome measures. Pain 88 (2000) 287-294
18. Tavoli A., Montazeri A., Roshan R., Tavoli Z., and Melyani M. Depression and quality of life in cancer patients with and without pain: the role of pain beliefs. BMC Cancer 8 (2008) 177. http://www.biomedcentral.com/1471-2407/8/177 Last accessed February 26, 2010
19. Klepstad P., Dale O., Kaasa S., et al. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. Acta Anaesthesiol Scand 47 (2003) 725-731
20. Collins S.L., Faura C.C., Moore A., and McQuay H.J. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 16 (1998) 388-402
21. ® opioids have low abuse and tampering attractiveness relative to marketed opioids. J Pain 10 4 Suppl 1 (2009) S60